Waters Corporation and the Biochemical Society announce the opening of registration for the Biochemical Society’s Quantitative Proteomics Training Day and the ProteoMMX 3.0 Symposium,. The Quantitative Proteomics Training Day is aimed at researchers seeking to gain familiarity with the field of quantitative proteomics. ProteoMMX 3.0, following immediately after the Training Day, is dedicated to current thinking and state of the art research in quantitative proteomics.
Professor Rob Beynon at the Institute of Integrative Biology at the University of Liverpool is leading the Organizing Committee. “The Symposium really gets to grips with the nuances and uncertainties in quantitative mass spectrometry-based proteomics in a friendly and supportive meeting. It is particularly suitable for early career researchers and newcomers to the field, especially if they attend the Training Day preceding the Symposium,” said Prof. Beynon.
The Symposium has been held three times previously with great success. Waters Corporation is the Enabling Sponsor of the ProteoMMX 3.0 Symposium.
Researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth.
Biomolecules are being synthesized in their mirror-image form, as part of a bigger long-term goal: to create simple, artificial biological systems in mirror-image form that correspond to those in nature but do not interact with the environment.